On Monday, Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX), skyrocketed 63.64% to $1.62.
Yesterday, Nymox Pharmaceutical Corporation, declared long-term clinical trial results from the Company’s NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically noteworthy(p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients contrast to controls. Trial participants comprised of 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found that after up to 2.8 years for NX-1207 single-injection treated patients there was a 68.2% reduction contrast to controls in the proportion of patients who had upgraded blinded biopsy results in the treated area and went on to require and receive radiation therapy and/or prostatectomy (surgery) (p=.0067). The new study also found that all instances of surgery or radiation, counting elective cases without upgrades, were reduced by 62.7% (p=.0035) in NX-1207 patients contrast to the randomized control group.
Long-term clinical outcome is a highly important measure of drug treatment efficacy. Patients were randomized to one of two doses of NX-1207 (2.5 mg or 15 mg) or to active surveillance (control). The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies, serial PSA measurements and long-term follow-up were performed on all patients treated and controls.
Paul Averback MD, CEO of Nymox said “These new results show the potential of NX-1207 to offer men with the most common form of low-grade prostate cancer a noteworthy tangible benefit in terms of avoidance of radiation and/or surgery and the related risks, discomforts, and permanent side effects. The results show a noteworthy positive effect from a single painless injection which is very exciting.”
Nymox Pharmaceutical Corporation, a biopharmaceutical company, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, in addition to AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimers disease.
Shares of Genetic Technologies Limited (NASDAQ:GENE), jumped 22.70% to $5.19.
Yesterday, Genetic Technologies, declared that a further two (2) new breast health centres will start to offer BREVAGenplus® to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company formerly declared were set to adopt BREVAGenplus, of which all six (6) have in fact offered samples during the March 2015 quarter.
With an additional number of new breast health centres predictable to follow suit later in calendar year 2015, the Company reiterates that it anticipates sales growth to accelerate in the second half of calendar 2015 and beyond.
Importantly, the Company believes that the adoption of BREVAGenplus by a total of eight (8) new breast health centres validates the company’s recently re-focused sales and marketing strategy, declared in September 2014, whereby the Company shifted its focus to these large facilities. While these centres are more complex entities with longer sales cycles, they offer higher and more stable long-term revenue potential.
The Company is working closely with these pivotal breast health centres and referring health care practitioners to ensure the creation of a personalised comprehensive breast cancer risk assessment approach in which BREVAGenplus plays an integral role. In this way, the Company aims to reinforce the benefits of the test, ease its adoption by the new clinics and ensure its routine use by them.
By working with these breast health centres and health care practitioners, the Company has developed a protocol where women who may be at noteworthy risk and have little to no family history of breast cancer, are being screened. Pilot programs have been instituted which essentially create a “safety net” for their patients, by assessing both hereditary in addition to sporadic breast cancer risk.
Genetic Technologies Limited CEO Mr. Eutillio Buccilli added, “This significantly changes the landscape; the paradigm shifts from detection and intervention to risk assessment, prevention and even earlier detection.”
Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders.
At the end of Monday’s trade, Shares of Novogen Limited (NASDAQ:NVGN), gained 20.97% to $9.23, hitting its highest level.
Yesterday, Novogen Limited advised that it has reached definitive contracts recently to issue about 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of about AU$15,500,000. The closing of the Placement is predictable to occur on or about 24 April 2015 and is subject to satisfaction of customary closing conditions. The issue of the attaching options under the Placement is subject to shareholder approval.
HC Wainwright & Co. is the exclusive placement agent for the Placement.
Under the terms of the Placement and the Rights Issue, the Company proposes to raise up to AU$30,500,000 through the issue of an aggregate of up to about 98.7 million fully-paid ordinary shares at a price of AU$0.30 each, comprising about 51 million shares under the Placement and up to about 47 million shares under the Rights Issue.
Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which comprise Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, counting glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer.
Finally, Uranium Energy Corp. (NYSEMKT:UEC), ended its last trade with 18.47% gain, and closed at $1.86, after Amir Adnani, CEO, President, and Director of Uranium Energy, bought 10,000 shares of the company in a transaction last Wednesday, according to an SEC filing. He purchased the shares at $1.50 apiece for a total transaction value of $15,000.
Additionally, Forbes stated a bullish outlook for uranium prices in an article on Friday. Japan shut down all of its nuclear reactors in the wake of the Fukushima disaster in March 2011, but Japanese Prime Minister Shinzo Abe plans to restart the nation’s nuclear industry with a aim of sourcing 20% of the nation’s electricity needs from nuclear power by 2030.
Forbes noted that Japan’s restarting of its nuclear power plants would bolster uranium prices, “as this will remove the biggest psychological barrier for global investors to invest in uranium or the uranium mining industry.”
Uranium Energy Corp. engages in the exploration, extraction, and processing of uranium concentrates on projects located in the United States and the Republic of Paraguay. As of July 31, 2014, it had mineral rights in uranium projects located in the states of Arizona, Colorado, New Mexico, Texas, and Wyoming, in addition to in the Republic of Paraguay.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
